Major developments in adjuvant treatment of early HER2-positive breast cancer
Alexandra King
This article has no abstract so we have provided the first paragraph of the full text.
A recent paper by Piccart-Gebhart et al. published in the New England Journal of Medicine presents one of the most important developments in the treatment of early breast cancer since the introduction of tamoxifen. The international, open-label, randomized herceptin adjuvant (HERA) (Breast International Group [BIG] 01-01) trial reported an approximate 50% decrease in the rate of disease recurrence in patients receiving adjuvant trastuzumab.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.